ASTRAZENECA PROVIDES UPDATE ON SELUMETINIB IN UVEAL MELANOMA

AstraZeneca today announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing.

Selumetinib is a MEK inhibitor in late-stage development, with a primary programme in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase III study in differentiated thyroid cancer and in a Phase II registration study in patients with neurofibromatosis Type 1.

Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca, said: "Selumetinib is supported by a strong development programme with different scientific rationale in multiple tumour types as both monotherapy and in alternative combinations. The findings from SUMIT have no impact on the other studies and we look forward to presenting the data in due course."

– ENDS –

NOTES TO EDITORS

About Selumetinib in Uveal Melanoma

Selumetinib, licensed from Array BioPharma Inc. in 2003, inhibits the MEK enzyme in the RAS/RAF/MEK/ERK pathway in cancer cells to prevent the tumour from growing.

The Selumetinib in Uveal Melanoma Investigator Trial (SUMIT) is a randomised, double-blind, placebo controlled trial being carried out in 45 centres, across 11 countries.

Uveal melanoma is an orphan disease in which cancer cells grow in the tissues of the eye. It is the most common primary intraocular malignancy in adults and comprises 5% of all melanomas1,2. There are currently no effective treatments for advanced uveal melanoma and in April 2015, selumetinib was granted Orphan Drug Designation by the US Food and Drug Administration in recognition of the need for new, safe and effective therapies for the disease3.

About AstraZeneca in Oncology

Oncology is a therapeutic area in which AstraZeneca has a deep-rooted heritage. It will be potentially transformational for the company's future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we are aiming to bring six new cancer medicines to patients.

Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and haematological cancers. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

References

Egan KM, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239–51
Ramaiya KJ, Harbour JW. Current management of uveal melanoma. Expert Rev Ophthalmol 2007; 2:939–46
US Food and Drug Administration. Developing Products for Rare Diseases & Conditions. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm Accessed on 08 July 2015

CONTACTS

Media Enquiries

 

 

Esra Erkal-Paler

UK/Global

+44 20 7604 8030

 

Vanessa Rhodes

UK/Global

+44 20 7604 8037

 

Ayesha Bharmal

UK/Global

+44 20 7604 8034

 

Jacob Lund

Sweden

+46 8 553 260 20

 

Michele Meixell

US

+ 1 302 885 6351

 

 

 

Investor Enquiries

 

 

UK

 

 

Thomas Kudsk Larsen

 

+44 20 7604 8199  

+44 7818 524185

Eugenia Litz

Respiratory, Inflammation and Autoimmunity

+44 20 7604 8233  

+44 7884 735627

Nick Stone

Cardiovascular and Metabolic Disease

+44 17 6326 3994  

+44 7717 618834

Karl Hård

Oncology

+44 20 7604 8123

+44 7789 654364

Craig Marks

Infection, Neuroscience and Gastrointestinal Disease

+44 20 7604 8591 

+44 7881 615764

Christer Gruvris

 

+44 20 7604 8126

+44 7827 836825

US

 

Dial / Toll-Free

  +1 301 398 3251

+1 866 381 7277

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.